Pricing and reimbursement of novel oncology drugs in Sweden.
作者信息
Haglund Mattias, Miller Eric
机构信息
IIB Partner AB, Sweden.
Optio Biopharma Solutions, LLC, USA.
出版信息
J Mark Access Health Policy. 2014 Dec 9;2. doi: 10.3402/jmahp.v2.25925. eCollection 2014.
Abstract
摘要
相似文献
1
Pricing and reimbursement of novel oncology drugs in Sweden.瑞典新型肿瘤药物的定价与报销
J Mark Access Health Policy. 2014 Dec 9;2. doi: 10.3402/jmahp.v2.25925. eCollection 2014.
2
Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.药品多适应症和联合用药定价与报销：通过加快采用新创新来改善医疗保健的机会。
Appl Health Econ Health Policy. 2018 Apr;16(2):157-165. doi: 10.1007/s40258-018-0377-7.
3
Pricing and reimbursement of drugs in Sweden.瑞典药品的定价与报销
Eur J Health Econ. 2002;3(1):66-70. doi: 10.1007/s10198-001-0094-1.
4
Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.药品报销政策的变化会影响药品支出吗？对瑞典1986 - 2002年成本、用量及单位用量成本趋势的中断时间序列分析。
Health Policy. 2006 Dec;79(2-3):231-43. doi: 10.1016/j.healthpol.2006.01.007. Epub 2006 Feb 13.
5
Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.捷克共和国和瑞典的药品定价与报销
Pharm World Sci. 2008 Jan;30(1):57-64. doi: 10.1007/s11096-007-9141-z. Epub 2007 Jun 23.
6
The costs and benefits of regulations for reimbursement of new drugs.新药报销规定的成本与效益。
Health Policy. 2006 Dec;79(2-3):337-44. doi: 10.1016/j.healthpol.2006.02.004. Epub 2006 Mar 20.
7
Pricing and reimbursement of pharmaceuticals in Sweden.瑞典药品的定价与报销
Pharmacoeconomics. 1994;6 Suppl 1:51-60. doi: 10.2165/00019053-199400061-00013.
8
Analysing criteria for price and reimbursement of orphan drugs in Spain.西班牙罕见病药物的定价与报销分析标准
Farm Hosp. 2019 Jul 1;43(4):121-127. doi: 10.7399/fh.11147.
9
Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.中东欧国家的药品监管：当前综述
Front Pharmacol. 2017 Dec 18;8:892. doi: 10.3389/fphar.2017.00892. eCollection 2017.
10
Drug pricing and reimbursement decision making systems in Mongolia.蒙古国的药品定价与报销决策系统
J Pharm Policy Pract. 2017 Feb 27;10:11. doi: 10.1186/s40545-017-0098-6. eCollection 2017.
引用本文的文献
1
Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?用于罕见病适应症的肿瘤药物：针对这一特定药物类别，卫生技术评估流程是如何演变的？
Clinicoecon Outcomes Res. 2017 Jun 10;9:327-342. doi: 10.2147/CEOR.S134230. eCollection 2017.
本文引用的文献
1
Are payers treating orphan drugs differently?支付方对罕见病药物的待遇是否有所不同？
J Mark Access Health Policy. 2014 Jan 15;2. doi: 10.3402/jmahp.v2.23513. eCollection 2014.
2
Market uptake of orphan drugs--a European analysis.孤儿药的市场接受度——欧洲分析。
J Clin Pharm Ther. 2012 Dec;37(6):664-7. doi: 10.1111/j.1365-2710.2012.01364.x. Epub 2012 Jun 26.
Zotero 插件